Abstract PO3-13-06: TILs are an independent prognostic factor in early-stage TNBC patients achieving pathologic complete response after neoadjuvant chemotherapy
Maria Vittoria Dieci(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Filippo de Braud(University of Milan), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Federica Miglietta(University of Padua), Fabio Girardi(London School of Hygiene & Tropical Medicine), Grazia Maria Vernaci(University of Padua), Andrea Vingiani(Istituti di Ricovero e Cura a Carattere Scientifico), Matteo Fassan(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Giancarlo Pruneri(University of Milan), Lorenzo Nicolè(University of Padua), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Davide Massa(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Riccardo Lobefaro(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 0
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830